Lenacapavir and Fostemsavir in Multidrug-Resistant HIV-1: Real-World Data
A single-center French retrospective cohort documents virological outcomes, resistance emergence, and therapeutic drug monitoring for two novel antiretrovirals in heavily treatment-experienced people with HIV-1, reinforcing adherence as the dominant determinant of success.
New HIV drugs show promise for resistant cases in France.
Lenacapavir and fostemsavir are new treatment options for managing multidrug-resistant HIV-1, offering hope in complex cases where traditional therapies fail. In a cohort of 21 patients, 82% of those previously viremic achieved viral suppression, with poor adherence linked to treatment failure and resistance. Real-world data confirm the effectiveness and safety of lenacapavir and fostemsavir for multidrug-resistant HIV-1, highlighting the importance of adherence in achieving optimal outcomes. Lenacapavir and fostemsavir are effective options for multidrug-resistant HIV-1 with adherence support crucial to treatment success.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Boujamline S, Boschi C, Bes-Barlandier H, Tomei C, Menard A, Mokhtari S, Ravaux I, Belkhir Y, Neant N, Solas C, Colson P, Million M
Citation:Boujamline S, Boschi C, Bes-Barlandier H, et al. Real-World Experience With Lenacapavir and/or Fostemsavir as Emerging Therapies for the Management of Multidrug-Resistant HIV-1 in Southeastern France. Journal of medical virology. 2026;98(9):e71149. doi:10.1002/jmv.71149